PHARMATHENE INC (PIP) Upgraded by Zacks to OUTPERFORM

Zacks Investment Research upgraded shares of PHARMATHENE INC (PIP) from NEUTRAL to OUTPERFORM on July 10, 2012, with a target price of $1.70.

PharmAthene Inc. is a biodefense company formed to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror. PharmAthene's lead programs include Valortim and Protexia.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on PHARMATHENE INC (PIP),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .